a preparation which reduces a concentration of a free fatty acid and / or fibrinogen in the blood, an agent for reducing the amount of a free fatty acid in the blood, an agent for reducing the amount of fibrinogen in the blood, a method for preventing or treating hyperacidemia of free fatty acid, metabolic syndrome, type II diabetes, complications caused by type II diabetes, lipotoxicity, abnormal lipid metabolism, glucose intolerance, impaired insulin secretion, liver fat, hypo-high density lipoproteinemia, or thrombosis, and use of a preparation

摘要

PREPARATION THAT REDUCES A CONCENTRATION OF A FREE FATTY ACID AND / OR FIBRONOGEN IN THE BLOOD, AGENT FOR REDUCING THE QUANTITY OF A FREE FATTY ACID IN THE BLOOD, AGENT FOR REDUCING THE AMOUNT OF FIBRINOGEN IN THE BLOOD, METHOD OF DETERMINATION OF TREATMENT OF TREATMENT FREE FATTY ACID, METABOLIC SYNDROME, DIABETES TYPE II, COMPLICATIONS CAUSED BY DIABETES TYPE II, LIPOTOXICITY, ABNORMAL PILID METABOLISM, INTOLERANCY TO GLUCOSE, HARMFUL HYDROPULUS, HYDRANT, HYDROPULUS, A PREPARATION It is the preparation of a preparation (pharmaceutical composition) to reduce a concentration of a free fatty acid and / or fibrinogen in the blood. The preparation contains a statin agent comprising at least one statin compound having a benzopyridine skeletal structure (for example, pitavastatin) and a fibrate agent (for example, fenofibrate). The preparation is useful as a preventive or treatment agent for free fatty acid hyperacidemia, metabolic syndrome, or type II diabetes.